3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
23
Melanoma
21
Carcinoma, Renal Cell
21
Neoplasms
8
Lung Neoplasms
8
Colorectal Neoplasms
8
Squamous Cell Carcinoma of Head and Neck
7
Prostatic Neoplasms
7
Neoplasm Metastasis
6
Carcinoma, Transitional Cell
6
Carcinoma, Hepatocellular
6
Stomach Neoplasms
5
Rectal Neoplasms
5
Hodgkin Disease
5
Adenocarcinoma Of Esophagus
5
Triple Negative Breast Neoplasms
4
Ovarian Neoplasms
4
Nasopharyngeal Carcinoma
4
Endometrial Neoplasms
4
Uterine Cervical Neoplasms
3
Urinary Bladder Neoplasms
3
Thyroid Neoplasms
3
Pancreatic Neoplasms
3
Oropharyngeal Neoplasms
3
Multiple Myeloma
3
Leukemia, Myeloid, Acute
3
Esophageal Neoplasms
3
Colonic Neoplasms
3
Brain Neoplasms
3
Anus Neoplasms
3
Interventions
Pluvicto
2
testosterone 17 beta-cypionate
1
radium Ra 223 dichloride
1
olaparib
1
enzalutamide
1
darolutamide
1
alovudine
1
Radium-223
1
PSMA-617
1
Nivolumab
1
Gonadotropin-Releasing Hormone
1
Blood Specimen Collection
1
Androgen Antagonists
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metastatic Castration-resistant Prostate Cancer
×
Nivolumab
×
30 days
×
Clear all
NCT04109729
2026-06-01
Rad2Nivo
University of Utah
Phase 1
Active not recruiting
39 enrolled